Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery

References

• BockJThe jubilee of the first successful optic keratoplasty by Eduard ZimWien Klin Wochenschr195870381383 German13570067
   PubMedGoogle Scholar
• FaridMPirouzianASteinertRFFemtosecond laser keratoplastyInt Ophthalmol Clin201353556423221885
   PubMedGoogle Scholar
• MaumeneeAEClinical aspects of the corneal homograft reactionInvest Ophthalmol1962124425214471522
   PubMedGoogle Scholar
• ParksJJLeibowitzHMMaumeneeAEImmediate hypersensitivity reactions in the cornea of the guinea pigJ Immunol19628932332514483968
   PubMed Web of Science ®Google Scholar
• GermuthFGMaumeneeAESenterfitLBPollackADImmunohistologic studies on antigen-antibody reactions in the avascular cornea: I. Reactions in rabbits actively sensitized to foreign proteinJ Exp Med196211591992819867210
   PubMed Web of Science ®Google Scholar
• ReinhardTBöckingAPomjanskiNSundmacherRImmune cells in the anterior chamber of patients with immune reactions after penetrating keratoplastyCornea200221566111805509
   PubMed Web of Science ®Google Scholar
• ErdurmusMCohenEJYildizEHSteroid-induced intraocular pressure elevation or glaucoma after penetrating keratoplasty in patients with keratoconus or Fuchs dystrophyCornea20092875976419574912
   PubMed Web of Science ®Google Scholar
• HamrahPDanaMRCorneal antigen-presenting cellsChem Immunol Allergy200792587017264483
   PubMedGoogle Scholar
• HamrahPHaskovaZTaylorAWZhangQKsanderBRDanaMRLocal treatment with alpha-melanocyte stimulating hormone reduces corneal allorejectionTransplantation20098818018719623012
   PubMed Web of Science ®Google Scholar
• MaDHChenHCLaiJYMatrix revolution: molecular mechanism for inflammatory corneal neovascularization and restoration of corneal avascularity by epithelial stem cell transplantationOcul Surf2009712814419635246
   PubMed Web of Science ®Google Scholar
• VassilevaPIHergeldzhievaTGAvastin use in high risk corneal transplantationGraefes Arch Clin Exp Ophthalmol20092471701170619680676
   PubMed Web of Science ®Google Scholar
• FlynnTHOhbayashiMIkedaYOnoSJLarkinDFEffect of allergic conjunctival inflammation on the allogeneic response to donor corneaInvest Ophthalmol Vis Sci20074894044404917724186
   PubMed Web of Science ®Google Scholar
• NguyenPBarteFShinadaSYiuSCManagement of corneal graft rejection – a case series report and review of the literatureJ Clin Exp Ophthalmol20101100010321720570
   PubMedGoogle Scholar
• HillJCIveyACorticosteroids in corneal graft rejection: double versus single pulse therapyCornea1994133833887995059
   PubMed Web of Science ®Google Scholar
• WackerKGründemannCKernYInhibition of corneal inflammation following keratoplasty by birch leaf extractExp Eye Res201297243022360995
   PubMed Web of Science ®Google Scholar
• SundmacherRReinhardTHeeringPSix years’ experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective studyGer J Ophthalmol199214324361490144
   PubMedGoogle Scholar
• StanojlovicSSchlickeiserSAppeltCInfluence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survivalGraefes Arch Clin Exp Ophthalmol20102481447145620574747
   PubMedGoogle Scholar
• DanaMRYamadaJStreileinJWTopical interleukin 1 receptor antagonist promotes corneal transplant survivalTransplantation199763150115079175817
   PubMed Web of Science ®Google Scholar
• GoslingsWRYamadaJDanaMRCorneal transplantation in antibody-deficient hostsInvest Ophthalmol Vis Sci1999402502539888452
   PubMed Web of Science ®Google Scholar
• YamadaJDanaMRZhuSNAlardPStreileinJWInterleukin 1 receptor antagonist suppresses allosensitization in corneal transplantationArch Ophthalmol1998116135113579790635
   PubMedGoogle Scholar
• DanaMRDaiRZhuSYamadaJStreileinJWInterleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilegeInvest Ophthalmol Vis Sci19983970779430547
   PubMed Web of Science ®Google Scholar
• RandlemanBJStultingRDPrevention and treatment of corneal graft rejection: current practice patternsCornea20062528629016633028
   PubMed Web of Science ®Google Scholar
• RinneJRStultingRDCurrent practices in the prevention and treatment of corneal graft rejectionCornea1992113263281424653
   PubMed Web of Science ®Google Scholar
• WangTJWangIJHoJDChouHCLinSYHuangMCComparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority studyClin Ther201032445220171410
   PubMed Web of Science ®Google Scholar
• RazeghinejadMRKatzLJSteroid-induced iatrogenic glaucomaOphthalmic Res2012472668021757964
   PubMed Web of Science ®Google Scholar
• RachwalSDruzgalaPLiuZZVlasakJBrewsterMEPopEChemistry of loteprednol etabonate and related steroids. II. Reactions at ring C and NMR structural studies of the resulting compoundsSteroids1998631932019589553
   PubMed Web of Science ®Google Scholar
• DruzgalaPHochhausGBodorNSoft drugs – 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonateJ Steroid Biochem Mol Biol1991381491542004037
   PubMed Web of Science ®Google Scholar
• AlbertMWuWMWinwoodDBodorNLipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroidJ Biopharm Sci19912115125
   Google Scholar
• HowesJNovackGDFailure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administrationJ Ocul Pharmacol Ther1998141531589572541
   PubMed Web of Science ®Google Scholar
• BodorNBauchwaldPSoft drug design: general principles and recent applicationsMed Res Rev2000205810110608921
   PubMed Web of Science ®Google Scholar
• LaneSSHollandEJLoteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgeryJ Cataract Refract Surg20133916817323232255
   PubMed Web of Science ®Google Scholar
• StewartRHorwitzBHowesJNovackGDHartKDouble-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1J Cataract Refract Surg199824148014899818338
   PubMed Web of Science ®Google Scholar
• ComstockTLUsnerDWEffect of loteprednol etabonate ophthalmic suspension 0.5% on post-operative pain and discomfort. E-abstract. 2010American Society of Cataract and Refractive Surgery SymposiumBoston Convention and Exhibition Center, Boston, MA, USAApril 9–14, 2010
   Google Scholar
• FongRLeitritzMSiou-MermetRErbTLoteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trialClin Ophthalmol201261113112422888209
   PubMedGoogle Scholar
• StewartRSControlled evaluation of fluorometholone acetate and loteprednol etabonate in the treatment of postoperative inflammation following cataract surgeryInvest Ophthalmol Vis Sci200445Suppl 1U159
   Google Scholar
• OnerVTürkcüFMTaşMAlakuşMFIşcanYTopical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: efficacy and safetyJpn J Ophthalmol20125631231822622345
   PubMed Web of Science ®Google Scholar
• HolzerMPSolomonKDSandovalHPVromanDTComparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked studyJ Cataract Refract Surg200228939911777716
   PubMed Web of Science ®Google Scholar
• RajpalRKSiou-MermetRErbTComstockTResolution of anterior chamber cells and flare with loteprednol etabonate 0.5% gel: new treatment for post-cataract inflammation and pain. E-abstract 1536057. 2013American Society of Cataract and Refractive Surgery SymposiumMoscone Center/SF Marriott Marquis, San Francisco, CA, USAApril 19–23, 2013
   Google Scholar
• BarkerNHHendersonTRRossCACosterDJWilliamsKACurrent Australian practice in the prevention and management of corneal allograft rejectionClin Experiment Ophthalmol20002835736011097282
   PubMed Web of Science ®Google Scholar
• HollandEJDjalilianARSandersonJPAttenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantationCornea2009281139114319770719
   PubMed Web of Science ®Google Scholar
• RajpalRKRoelLSiou-MermetRErbTEfficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgeryJ Cataract Refract Surg20133915816723218817
   PubMed Web of Science ®Google Scholar
• ComstockTLPaternoMRSinghAErbTDavisESafety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgeryClin Ophthalmol2011517718621383946
   PubMedGoogle Scholar
• PoleyBJLindstromRLSamuelsonTWLong-term effects of phacoemulsification with intraocular lens implantation in normotensive and ocular hypertensive eyesJ Cataract Refract Surg20083473574218471626
   PubMed Web of Science ®Google Scholar
• HowesJFLoteprednol etabonate: a review of ophthalmic clinical studiesPharmazie20005517818310756536
   PubMed Web of Science ®Google Scholar
• ForteLEconomic evaluation of loteprednol etabonate versus prednisolone in treatment of ocular inflammation. Poster abstract #738320. 2010American Society of Cataract and Refractive Surgery SymposiumBoston Convention and Exhibition Center, Boston, MA, USAApril 9–14, 2010
   Google Scholar
• DruzgalaPWuWMBodorNOcular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyesCurr Eye Res1991109339371959381
   PubMed Web of Science ®Google Scholar
• AmonMBusinMLoteprednol etabonate ophthalmic suspension 0.5%: efficacy and safety for postoperative anti-inflammatory useInt Ophthalmol20123250751722707339
   PubMedGoogle Scholar
• HumayunMGottliebCC MDRafusePEIntraocular ophthalmic ointment following clear corneal phacoemulsification: clinical implicationsJ Cataract Refract Surg2006322135213817137997
   PubMed Web of Science ®Google Scholar
• AralikattiAKNeedhamADLeeMWPrasadSEntry of antibiotic ointment into the anterior chamber after uneventful phacoemulsificationJ Cataract Refract Surg20032959559712663030
   PubMed Web of Science ®Google Scholar
• RiedlMMacaSAmonMNennadalTKrugerABarisaniTIntraocular ointment after small-incision cataract surgery causing chronic uveitis and secondary glaucomaJ Cataract Refract Surg2003291022102512781294
   PubMed Web of Science ®Google Scholar
• ChenKHLinSYLiMJChengWTRetained antibiotic ophthalmic ointment on an intraocular lens 34 months after sutureless cataract surgeryAm J Ophthalmol200513974374515808189
   PubMed Web of Science ®Google Scholar
• WongJGBankASurgical removal of intraocular antibiotic ointment after routine cataract phacoemulsificationJ Cataract Refract Surg20063289089216765812
   PubMed Web of Science ®Google Scholar
• ChewJJLWernerLMackmanGMamalisNLate opacification of a silicone intraocular lens caused by ophthalmic ointmentJ Cataract Refract Surg20063234134616565014
   PubMed Web of Science ®Google Scholar
• WernerLSherJHTaylorJRToxic anterior segment syndrome and possible association with ointment in the anterior chamber following cataract surgeryJ Cataract Refract Surg20063222723516564997
   PubMed Web of Science ®Google Scholar
• The Loteprednol Etabonate Postoperative Inflammation Study Group 2A double-masked, placebo controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammationOphthalmology1998105178017869754192
   PubMed Web of Science ®Google Scholar